Indivior PLC Price & Performance (INVVY)

Indivior reported first-quarter earnings per share of $0.41, handily beating analyst expectations of $0.26, with revenue reaching $266 million. Despite a 6% year-on-year revenue decline, the company reaffirmed its 2025 guidance. Shares surged on investor optimism, buoyed by confidence in the SUBLOCADE product's growth prospects.123

Indivior is intensifying its focus on SUBLOCADE, its flagship opioid use disorder treatment, following new FDA-approved label changes that ease initiation and administration. The company is reallocating resources from R&D to sales and marketing, aiming for $725–$765 million in SUBLOCADE revenue this year amid fierce competition and funding headwinds.45

Indivior shares jumped almost 4% in recent trading, reflecting renewed investor confidence after robust Q1 results. Multiple analysts have reaffirmed buy ratings, citing the company’s strong product portfolio and positive insider sentiment. Despite recent volatility, forecasts remain bullish with significant upside potential projected for the next year.678